BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 8594244)

  • 1. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology.
    Soll AH
    JAMA; 1996 Feb; 275(8):622-9. PubMed ID: 8594244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical issues in the pathophysiology and management of peptic ulcer disease.
    Hunt RH; Malfertheiner P; Yeomans ND; Hawkey CJ; Howden CW
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):685-99. PubMed ID: 8590166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
    Howden CW
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S5-11. PubMed ID: 10597118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).
    Tefera S; Berstad A; Bang CJ; Nysaeter G; Hatlebakk JG; Olafsson S; Nesje LB; Hausken T; Berstad K; Hundal O
    Am J Gastroenterol; 1996 May; 91(5):935-41. PubMed ID: 8633584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.
    Liu CC; Lee CL; Chan CC; Tu TC; Liao CC; Wu CH; Chen TK
    Arch Intern Med; 2003 Sep; 163(17):2020-4. PubMed ID: 14504114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based clinical practice guidelines for peptic ulcer disease 2015.
    Satoh K; Yoshino J; Akamatsu T; Itoh T; Kato M; Kamada T; Takagi A; Chiba T; Nomura S; Mizokami Y; Murakami K; Sakamoto C; Hiraishi H; Ichinose M; Uemura N; Goto H; Joh T; Miwa H; Sugano K; Shimosegawa T
    J Gastroenterol; 2016 Mar; 51(3):177-94. PubMed ID: 26879862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy.
    Lanas A; Remacha B; Sáinz R; Hirschowitz BI
    Am J Gastroenterol; 2000 Feb; 95(2):513-9. PubMed ID: 10685760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs.
    Graham DY
    Am J Med; 2001 Jan; 110(1A):58S-61S. PubMed ID: 11166000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease.
    Penston JG
    Aliment Pharmacol Ther; 1996 Aug; 10(4):469-86. PubMed ID: 8853751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
    Avidan B; Melzer E; Keller N; Bar-Meir S
    Isr Med Assoc J; 2001 Mar; 3(3):163-5. PubMed ID: 11303370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of peptic ulcers: emerging issues.
    Freston JW
    World J Surg; 2000 Mar; 24(3):250-5. PubMed ID: 10658056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.
    Bianchi Porro G; Parente F; Imbesi V; Montrone F; Caruso I
    Gut; 1996 Jul; 39(1):22-6. PubMed ID: 8881802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating peptic ulcer: an ongoing challenge.
    Cohen MH
    J Am Osteopath Assoc; 1995 Apr; 95(4):239-41. PubMed ID: 7744624
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of NSAID-associated peptic ulcer disease.
    Melcarne L; García-Iglesias P; Calvet X
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):723-33. PubMed ID: 26775657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helicobacter pylori and peptic ulcer disease. Current evidence for management strategies.
    Chiba N; Lahaie R; Fedorak RN; Bailey R; Veldhuyzen van Zanten SJ; Bernucci B
    Can Fam Physician; 1998 Jul; 44():1481-8. PubMed ID: 9678277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of the peptic ulcer patient in the Helicobacter pylori age].
    Marshall BJ
    Enferm Infecc Microbiol Clin; 1994 May; 12 Suppl 1():36-40. PubMed ID: 7914434
    [No Abstract]   [Full Text] [Related]  

  • 19. No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease.
    Tytgat GN
    Aliment Pharmacol Ther; 1995; 9 Suppl 1():39-42. PubMed ID: 7495941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptic ulcer disease in the 1990s: an Asian perspective.
    Fock KM
    J Gastroenterol Hepatol; 1997 Jun; 12(6):S23-8. PubMed ID: 9195408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.